Switching from Semaglutide to Tirzepatide: What the Dosing Change Really Involves

The myth that tirzepatide 2.5mg is weaker than your current semaglutide dose

The most common misconception people arrive with is that starting tirzepatide at 2.5mg after months on semaglutide 1.7mg or 2.4mg represents a step backwards. It doesn't. The two milligram scales are unrelated: semaglutide and tirzepatide are different molecules with different molecular weights, different receptor targets and entirely different dose-response curves. A 2.5mg tirzepatide dose carries no meaningful comparison to a 2.5mg semaglutide dose, they aren't the same drug at the same size of portion.

Tirzepatide activates both GIP and GLP-1 receptors, giving it a dual mechanism that semaglutide, a single GLP-1 receptor agonist, doesn't share. That biological difference is part of why SURMOUNT-5, a 72-week head-to-head trial published in the New England Journal of Medicine (2025), found tirzepatide produced greater average weight reduction than semaglutide 2.4mg in adults with obesity who did not have diabetes. NICE's appraisal of tirzepatide (TA1026) similarly noted the indirect comparisons favour tirzepatide, though the committee acknowledged the evidence base continues to develop.

So when your prescriber recommends starting at 2.5mg tirzepatide, the job of that first pen is to let your system settle into a new mechanism, not to match what you were taking before. The dose titration that follows is where the clinical work happens. Letting that misconception go tends to make the first few weeks considerably less frustrating.

A side-by-side look at the two dosing schedules

Understanding where the numbers sit on each scale makes the transition easier to picture. Both medicines are once-weekly subcutaneous injections, both titrated by a prescriber in roughly four-week steps.

Sources: NHS medicines: tirzepatide; NHS medicines: semaglutide; MHRA approval announcement, 14 April 2026 (Wegovy 7.2mg single-dose pen). The table describes licensed schedules factually, what you start on and when you move up is a clinical decision, not a self-directed one. Missed doses, timing adjustments and pace of titration are addressed in your Patient Information Leaflet and with your prescriber.

What actually determines your starting tirzepatide dose after semaglutide

There is no universal formula that maps a semaglutide dose to a tirzepatide equivalent. A prescriber considers several things: how long you've been on semaglutide, what dose you're currently tolerating, how significant your GI side effects were, and your overall clinical picture. People who tolerated semaglutide well and reached maintenance may not need to restart at the absolute floor; people who found the GI adjustment difficult on semaglutide may benefit from more caution. The timing and clinical criteria for switching feed directly into that dose conversation.

At nume, transfer patients provide evidence of their current treatment before any switch is approved. That evidence (which dose, how long, any dose-increase documentation) is exactly what a prescriber needs to make a sensible recommendation. Our clinical team reviews every consultation personally; the decision never comes from a form alone.

Side effects to be aware of during the transition follow a broadly similar GI pattern to semaglutide: nausea, changes to bowel habit, occasional reflux or fatigue, typically most noticeable after starting or after a dose increase and settling over the following days to two weeks. The NHS's patient information for tirzepatide lists the full profile. Severe or persistent stomach pain that spreads to your back is a reason to seek medical attention promptly, as the MHRA flagged acute pancreatitis as an infrequent but serious risk with GLP-1 medicines in a January 2026 Drug Safety Update.

Semaglutide or tirzepatide: which is the right call for you

The trial data make tirzepatide look compelling on headline numbers. But the right medicine is the one that fits your health profile, your history with semaglutide, any contraindications your prescriber identifies, and your own preferences about the practical realities of treatment. Some people do very well on semaglutide long-term and have no reason to switch. Others plateau and want to explore a different mechanism, and if you are considering that direction, our guide to switching from Mounjaro to semaglutide covers what that process involves. A few switch and find tirzepatide's GI adjustment harder at first. For a fuller evidence-based breakdown, our comparison of the two medicines covers the trial findings in more detail, and the Wegovy versus Mounjaro page addresses the practical differences between the two branded options.

On cost: switching medicines changes the price, and the two tend to sit at different points in the market. A look at which is cheaper covers the context without oversimplifying it. Neither is cheap by any ordinary measure, and for a prescription medicine, the cheapest listing answers the wrong question. Legitimate, clinically supervised treatment from a GPhC-registered pharmacy (our registration: 9012878) is the standard that matters. Which medicine suits you is a clinical decision our prescribers make with you, not one to resolve from a comparison page alone. Speak to our prescribers to start that conversation.